The mild winter still impacted Green Landscaping (GLG) delivered a soft Q2 with sales 4% and 8% belo...
Another impressive margin lift Nolato reported Q2 EBITA 5% and 7% above ABGSCe and IR consensus, res...
Solid Q2, UK is the star of the show We saw signs of improvement for both Svedbergs and Roper Rhodes...
A strong report across the board Berner Industrier delivered a strong Q2 report, with orders up 12% ...
Redeye retains its positive view of CombinedX following a relatively soft Q2.
Q2 results Prevas reported a weaker-than-expected Q2'25, with sales of SEK 409m, up 3% y-o-y (4% bel...
Q2 results Q2 sales were SEK 3,601m (+1% vs. ABGSCe 3,550m), -13% y-o-y.
Redeye comments on Absolent’s Q2 numbers which overall were a notch below our forecast.
Redeye states that Eniro’s Q2 2025 report was slightly weaker across all items.
Redeye comments on Arise’s Q2 report, which saw higher production than expected, driving the segment...
Q2 details Infrea delivered a mixed report with higher sales and lower adj.
Redeye provides an initial comment on the Q2 2025 report from Tradedoubler, which showed solid growt...
Q2 details Sales SEK 427m (5% vs ABG 408m, -1% vs cons 421m).
Q2 details Sales were 2% above our expectations, with 7% organic sales growth (ABGSCe +4%), which in...
Q2 results Orders were up 12% y-o-y and 3% below our estimate.
Q2'25 outcome The Q2 report was above consensus' expectations.
Oriola posted strong growth figures in Q2, with net sales up 12% y/y and both segments showing doubl...
Consti's net sales in Q2 amounted to EUR 84.8m, surpassing our estimate (Evli est.
Tiratricol now has US FDA Breakthrough Therapy Designation for MCT8 deficiency, which is essential f...
Redeye provides its first take on Cellavision’s Q2 report 2025, published this morning.